Management of Heart Failure Patients with ACE Inhibitor-Induced Dry Cough
Understanding the Clinical Scenario
- The dry cough in a heart failure patient on ACE inhibitors occurs in 5-35% of patients taking these medications, characterized by a dry, tickling or scratching sensation in the throat, with onset ranging from hours to months after starting therapy, and is not dose-dependent, more common in women, non-smokers, and persons of Chinese origin 2, 3, 1
Management Algorithm
- The American College of Chest Physicians provides a Grade B recommendation for discontinuing the ACE inhibitor immediately, as this is the only uniformly effective treatment for ACE inhibitor-induced cough, with cough typically resolving within 1-4 weeks after cessation 2, 3, 1
- The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend switching to an ARB, which has a Class I, Level A recommendation, such as valsartan, to maintain guideline-directed medical therapy 1
Beta-Blocker Therapy with Nebivolol
- The European Society of Cardiology recommends continuing or initiating nebivolol as part of guideline-directed medical therapy for heart failure, as nebivolol reduces morbidity and mortality in heart failure patients, and is a first-line treatment along with ACE inhibitors (or ARBs when ACE inhibitors are not tolerated) for NYHA class I-IV heart failure 4, 5
Practical Implementation
- The initial dose of nebivolol should be 1.25 mg once daily, with a target dose of 5-10 mg once daily, and titration at 2-week intervals as tolerated, with monitoring of blood pressure, heart rate, renal function, and potassium levels within 1-2 weeks after initiation or dose changes 4, 1